Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 4, 2000, Pages 365-370

  Özkan, Yalçn ^a   Atay, Tamer ^a   Dikmen, Necati ^a   Işimer, Aşkn ^a   Aboul Enein, Hassan Y ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Bioanalyt and Drug Devmt Lab   (Saudi Arabia)

Author keywords

Cyclodextrin; Dissolution rate; Gliclazide; Neutralization; Recrysstalization; Solubility

Indexed keywords

BETA CYCLODEXTRIN; GLICLAZIDE;

ARTICLE; COMPLEX FORMATION; CRYSTALLIZATION; DISSOLUTION; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; CYCLODEXTRINS; EXCIPIENTS; GLICLAZIDE; HYPOGLYCEMIC AGENTS; KINETICS; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; X-RAY DIFFRACTION;

EID: 0033996850     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00063-1     Document Type: Article

References (18)

1. Ammar H.O., Ghorab M., El-Nahhas S.A., Emara L.H., Makram T.S. Inclusion complexation of furosemide in cyclodextrins. Pharmazie. 54:1999;142-144.
2. Andersen F.A., Bundgaard H. Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions. Int. J. Pharm. 19:1984;189-197.
3. Bekers O., Uijtendaal E.V., Beijnen J.H., Bult A., Underberg W.J.M. Cyclodextrins in pharmaceutical field. Drug Dev. Ind. Pharm. 17:1991;1503-1549.
4. Blanco J., Vila-Jato J.L., Otero F., Anguiano S. Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev. Ind. Pharm. 17:1991;943-945.
5. Chow D., Karara A. Characterization, dissolution and bioavailability in rats of ibuprofen-β-cyclodextrin complex system. Int. J. Pharm. 28:1986;95-101.
6. Gillmann A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gillmann's The Pharmacological Basis Therapeutics. 8th edn. 1990;1485-1486 Pergamon, Maxwell House, New York, USA.
7. Griffiths D.W., Bender M.L. Cycloamyloses as catalysts. Adv. Catal. 23:1973;209-261.
8. Higuchi T. Mechanism of sustained action medication. J. Pharm. Sci. 52:1963;1145-1149.
9. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4:1965;117-212.
10. Langenbucher F. Parametric representation of dissolution rate curves by the RRSBW distrubution. Pharm. Ind. 38:1976;472-477.
11. Moyano J.R., Arias-Blanco M.J., Gines J.M., Giordano F. Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complexes. Int. J. Pharm. 148:1997;211-217.
12. Moyano J.R., Arias-Blanco M.J., Gines J.M., Rabasco A.M., Perez-Martinez J.I., Mor M., Giordano F. Nuclear magnetic resonance investigations of the inclusion complexation of gliclazide with -β-cyclodextrin. J. Pharm. Sci. 86:1997;72-75.
13. Pitha J., Milecki J., Fales H., Pannell L., Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm. 29:1986;73-82.
14. Reynolds J.E.F. Martindale. The Extra Pharmacopoeia. 30th edn. 1993;279-280 The Pharmaceutical Press, London.
15. Saenger W. Cyclodextrin inclusion compounds in research and laboratory. Angew. Chem. Int. Ed. Engl. 19:1980;344-362.
16. Seo H., Tsruoka M., Hashimato T., Fujinaga T., Otagiri M., Uekama K. Enhancement of oral bioavailability of spiranolactone by beta and gamma-cyclodextrin complexations. Chem. Pharm. Bull. 31:1983;286-291.
17. Szejli J. Cyclodextrin Technology. 1988;1-78 Kluwer Academic Publishers, Dordrecht.
18. The United States Pharmacopeia, 995. 23rd Revision, Rand Mc Nally, Tounton, MA, pp. 1791-1792, pp. 2220-2221.